Naloxone nasal spray: a new treatment option for opioid overdose

Nyxoid (naloxone dihydrate) is a single-dose nasal spray for the emergency treatment of known or suspected opioid overdose in both medical and non-medical settings.

Nyxoid is intended to be administered as a part of a resuscitation intervention in suspected opioid overdose, generally in a non-medical setting. | ALAIN DEX, PUBLIPHOTO DIFFUSION/SCIENCE PHOTO LIBRARY
Nyxoid is intended to be administered as a part of a resuscitation intervention in suspected opioid overdose, generally in a non-medical setting. | ALAIN DEX, PUBLIPHOTO DIFFUSION/SCIENCE PHOTO LIBRARY

Nyxoid should only be made available once the suitability and competence of an individual to administer naloxone in the appropriate circumstances has been established. Patients or any other person who may be in a position to administer Nyxoid must be instructed in its proper use and the importance of seeking medical assistance.

A single dose (1.8mg naloxone) should be administered into one nostril as soon as possible, followed by a second dose after two to three minutes if there is no response. If the patient responds initially then relapses into respiratory depression the second dose should be administered immediately. Any further doses should be administered into alternate nostrils.

Nyxoid is licensed for use in adults and adolescents aged 14 years and older. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in